8-K: Surrozen Appoints New CFO Amidst Widening Q3 Loss

Surrozen, Inc. announced Andrew Maleki as its new CFO and reported a significant net loss of $71.6 million for Q3 2025, alongside progress in its ophthalmology pipeline.

Summary

• Andrew Maleki has been appointed Chief Financial Officer, effective November 12, 2025, bringing over a decade of biotech experience in corporate strategy, business development, and capital raising.
• Charles Williams will transition from his dual role as CFO and COO to solely serve as Chief Operating Officer and Secretary, focusing on strategic initiatives and corporate development.
• Cash and cash equivalents were $81.3 million as of September 30, 2025, a decrease from $90.4 million as of June 30, 2025.
• The company reported a net loss of $71.6 million, or ($8.36) per share, for the third quarter ended September 30, 2025, significantly higher than the net loss of $1.4 million, or ($0.44) per share, for the same period in 2024.
• Collaboration and license revenue was zero for Q3 2025, compared to $10.0 million in Q3 2024, which was attributable to a milestone achieved under the Boehringer Ingelheim agreement.
• Research service revenue from a related party increased to $1.0 million for Q3 2025 from zero in Q3 2024, driven by collaboration with TCGFB, Inc.
• Research and Development (R&D) expenses increased to $7.8 million in Q3 2025 from $5.2 million in Q3 2024, primarily due to increased manufacturing costs, lab expenses, and consulting fees for ophthalmology programs.
• General and Administrative (G&A) expenses rose to $4.1 million in Q3 2025 from $3.6 million in Q3 2024, mainly due to higher professional service fees.
• A significant non-cash loss on change in fair value of tranche liability of $40.7 million was recorded in Q3 2025.
• Other expense, net, was $20.9 million in Q3 2025, primarily driven by the non-cash change in fair value of warrant liabilities.
• The company continues to progress its lead ophthalmology candidates, SZN-8141 and SZN-8143, for retinal diseases and remains on track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026.
• Scientific presentations highlighting 'Next Generation Wnt Therapeutics in Retinal Diseases' were made at the Eyecelerator (AAO) Meeting on October 16, 2025, and are scheduled for the Ophthalmology Innovation Source (OIS) conference on November 22, 2025.

Sentiment

Score: 3

Explanation: While there are positive developments in management and pipeline progress, the substantial increase in net loss, significant cash burn, and absence of collaboration revenue indicate severe financial deterioration and high operational risk, overshadowing the positive news.

Positives

• Appointment of Andrew Maleki as Chief Financial Officer strengthens the management team with over a decade of experience in corporate strategy, business development, and capital raising.
• Charles Williams' transition to a dedicated Chief Operating Officer role allows for intensified focus on strategic initiatives, corporate development, and enterprise execution.
• Continued progress in the ophthalmology pipeline with lead candidates SZN-8141 and SZN-8143 for retinal diseases.
• On track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026, indicating advancement towards clinical development.
• Increased interest income to $911 thousand in Q3 2025 from $431 thousand in Q3 2024.
• Increased research service revenue from a related party to $983 thousand in Q3 2025 from zero in Q3 2024.

Negatives

• Net loss significantly widened to $71.6 million ($8.36 per share) in Q3 2025, compared to $1.4 million ($0.44 per share) in Q3 2024.
• Collaboration and license revenue decreased to zero in Q3 2025 from $10.0 million in Q3 2024.
• Cash and cash equivalents declined to $81.3 million as of September 30, 2025, from $90.4 million as of June 30, 2025.
• A substantial non-cash loss on change in fair value of tranche liability of $40.7 million was recorded in Q3 2025.
• Other expense, net, increased significantly to $20.9 million in Q3 2025, primarily due to non-cash change in fair value of warrant liabilities.
• Research and Development expenses increased by $2.7 million due to manufacturing, lab, and consulting fees for ophthalmology programs, and $0.6 million in employee-related expenses.

Risks

• Risks and uncertainties related to the initiation, cost, timing, progress, and results of research and development activities, preclinical and clinical trials for product candidates.
• The company's ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising.
• Ability to identify, develop, and commercialize drug candidates successfully.
• Ability to successfully complete preclinical and clinical studies for product candidates.
• Potential effects arising from volatility in global economic, political, regulatory, and market conditions.
• Reliance on future success-based development, regulatory, and commercial milestone payments and royalties from the Boehringer Ingelheim partnership.

Future Outlook

Surrozen anticipates submitting an Investigational New Drug (IND) application for its lead candidate SZN-8141 in 2026. The company expects potential future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales from its partnership with Boehringer Ingelheim. Management also highlights the strengthening of its leadership team to drive enterprise-wide execution focused on long-term growth and success.

Management Comments

• "We continue to make significant progress with our ophthalmology pipeline and to further strengthen the depth and breadth of our management team to drive enterprise-wide execution focused on long-term growth and success." Craig Parker, President and Chief Executive Officer of Surrozen.
• "With the addition of Andrew Maleki to our strong leadership team, we are well positioned to advance our novel therapeutics toward clinical development while expanding our strategic capabilities and execution." Craig Parker, President and Chief Executive Officer of Surrozen.

Industry Context

Surrozen operates in the highly competitive biotechnology sector, specifically focusing on Wnt pathway modulation for tissue repair and regeneration in ophthalmology. The development of novel treatments for severe eye diseases like Diabetic Macular Edema (DME) and neovascular Age-Related Macular Degeneration (wet AMD) is a significant area of unmet medical need, with current standard of care often involving anti-VEGF monotherapies. Surrozen's approach, combining Fzd4 agonism with VEGF and/or IL-6 antagonism, aims to differentiate its candidates (SZN-8141, SZN-8143) from existing therapies by promoting normal retinal vessel regrowth while suppressing pathological growth. The appointment of a CFO with strong capital raising and corporate development experience is crucial for a biotech company advancing candidates towards clinical development, especially given the high capital requirements of the industry.

Comparison to Industry Standards

• Surrozen's Wnt-based therapeutics, specifically SZN-8141 and SZN-8143, aim to provide benefits over current standard-of-care anti-VEGF monotherapies for retinal diseases like DME and wet AMD. Major players in this space include Regeneron with Eylea and Novartis with Lucentis and Beovu, which primarily focus on VEGF inhibition.
• The company's strategy of combining Fzd4 agonism with VEGF antagonism (SZN-8141) and additionally IL-6 antagonism (SZN-8143) represents a multi-modal approach designed to offer differentiation from single-target therapies.
• Preclinical data demonstrating SZN-8141 and SZN-8143's ability to stimulate Wnt signaling, induce normal retinal vessel regrowth, and suppress pathological vessel growth suggests a potentially regenerative mechanism, which could be a significant advancement over purely inhibitory treatments.
• The strategic partnership with Boehringer Ingelheim for SZN-413, including an upfront payment and potential milestone payments, aligns with common industry practices for early-stage biotech companies to leverage larger pharmaceutical partners for advanced development and commercialization, de-risking their pipeline.

Management Changes

Corporate Governance

Related Party Transactions

• Research service revenue from a related party was $983 thousand for the quarter ended September 30, 2025, driven by the collaboration with TCGFB, Inc. for TGFantibodies.

Stakeholder Impact

• Shareholders: The significant increase in net loss and declining cash position could negatively impact investor confidence and share price. The appointment of a new CFO with capital raising experience might signal future dilution if new capital is raised, though pipeline progress offers long-term potential.
• Employees: The strengthening of the management team with a new CFO and a dedicated COO role could provide clearer strategic direction and operational focus, potentially improving morale and efficiency.
• Customers/Partners: Continued progress in the ophthalmology pipeline and scientific presentations reinforce the company's commitment to developing novel therapeutics. The ongoing Boehringer Ingelheim partnership remains a key strategic alliance.
• Creditors: The declining cash balance and increasing liabilities, particularly warrant and tranche liabilities, could be a concern, although the current cash position of $81.3 million provides some operational runway.

Next Steps

• Submit an Investigational New Drug (IND) application for SZN-8141 in 2026.
• Present an overview of Next Generation Wnt Therapeutics in Retinal Diseases at the Ophthalmology Innovation Source (OIS) conference on November 22, 2025.
• Continue to progress lead candidates SZN-8141 and SZN-8143 in retinal diseases.

Key Dates

Recommendation

The substantial widening of the net loss to $71.6 million, coupled with a significant decline in collaboration revenue and a quarter-over-quarter decrease in cash, indicates severe financial deterioration. While the appointment of a new CFO and pipeline progress are positive, the current financial burn rate and large non-cash liabilities present considerable short-term risks. The company's ability to fund future operations and clinical trials is explicitly highlighted as a risk, suggesting potential future dilution. Investors should consider the substantial financial headwinds despite the long-term potential of the pipeline.

Keywords

Biotechnology, Ophthalmology, Wnt pathway, Retinal diseases, SZN-8141, SZN-8143, SZN-413, SEC filing, Financial results, Q3 2025, CFO appointment, Corporate governance, Drug development, Clinical trials, IND application, Surrozen, SRZN, Tissue repair, Regeneration, Diabetic Macular Edema, Wet AMD, Uveitic macular edema, Anti-VEGF